News about Drug Discovery & Development

Hoth Therapeutics Collaborates with OnTargetx R&D Inc. to Advance Research for its Cancer-Fighting Therapeutic 'HT-KIT'

This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.

Drug Discovery & Development | 11/02/2025 | By Manvi |  411

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Drug Discovery & Development | 10/02/2025 | By Aishwarya |  619

Jupiter Neurosciences Signs JOTROL Manufacturing Agreement with Catalent

Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation.

Drug Discovery & Development | 04/02/2025 | By Aishwarya |  415

Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management.

Drug Discovery & Development | 03/02/2025 | By Aishwarya |  715

Kenox Pharmaceuticals Enhances Capabilities to Boost Drug Development

Kenox Pharmaceuticals Inc has expanded its capabilities with small-scale non-sterile GMP facilities to support GLP pre-clinical studies, reinforcing its commitment to accelerating the development of innovative Orally Inhaled and Nasal Drug Products (OINDPs).

Drug Discovery & Development | 29/01/2025 | By Manvi |  399

FDA Grants Priority Review to Merck's Application for 'WELIREG'

Merck announced the US FDA has accepted for priority review a supplemental new drug application (sNDA) seeking approval of WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult and and pediatric patients (12 years and older).

Drug Discovery & Development | 27/01/2025 | By Manvi |  236

Glenmark Pharmaceuticals Unveils Generic Anticoagulant Injectable Emulsion

Glenmark's Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.

Drug Discovery & Development | 24/01/2025 | By Aishwarya |  736

Catalyst Pharmaceuticals Announces Launch of FIRDAPSE in Japan by DyDo

FIRDAPSE (amifampridine) is the only US FDA approved, evidence-based therapy for the treatment of LEMS in adults and pediatric patients six years of age and older.

Drug Discovery & Development | 22/01/2025 | By Aishwarya |  536

Absci and Owkin Partner to Propel Generative AI in Drug Discovery

Absci Corporation and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

Drug Discovery & Development | 21/01/2025 | By Manvi |  562

Iconovo and Lonza to Develop Formulation of Intranasal Biologic

This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.

Drug Discovery & Development | 14/01/2025 | By Aishwarya |  417